Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Takeaways - MDSpire

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • By

  • Darren Hargrave

  • Lynley V. Marshall

  • Nicolas André

  • Julie Krystal

  • Brian H. Ladle

  • Karen A. Robbins

  • Stephan Hois

  • Jon Armstrong

  • Sarah Donegan

  • June 9, 2026

  • 0 min

Share

  • 1

    An erratum was issued for a Phase I/II study on durvalumab and tremelimumab in pediatric patients with advanced solid tumors.

  • 2

    The correction addresses misalignment of numerical values in Table 1 under the subheader Tumor types.

  • 3

    A missing footnote related to histology was also noted in the original publication.

  • 4

    The corrected Table 1 includes references to various tumor types and treatment modalities.

  • 5

    The original article has been updated to reflect these corrections.

Original Source(s)

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • by Darren Hargrave, Lynley V. Marshall, Nicolas André, Julie Krystal, Brian H. Ladle, Karen A. Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

  • June 9, 2026

Related Content

Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology